Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2008

View Archived Issues

AT1-AAs implicated in pre-eclampsia in mouse studies

Novel treatment options for anemia described in recent GSK patent

NeoPharm reveals new agents for atopic dermatitis in recent patent

Subtype-selective GABA-A receptor modulator reduces neuropathic hypersensitivity in vivo

RGH-478 reduces pain in arthritis models

Biogen commences phase III Adentri trial in acute decompensated heart failure

Glycine transporter inhibitors identified at Merck for the treatment of schizophrenia

Pilot study finds no effect of atorvastatin on CSF HIV-1 infection

FRANCIS trial commences in patients within acute coronary syndrome

Indevus completes patient enrollment in phase III PRO-2000 trial

MMRC and Celgene collaborate on phase I/II pomalidomide trial

Alpharma rejects takeover proposal from King Pharmaceuticals

BioAlliance is granted main patent in Europe for Lauriad

Recent Mitsubishi Tanabe patent discloses new anxiolytic compounds

rhNRG-1 improves donor heart preservation in animal studies

Biovail gains Canadian approval for Ralivia for moderately severe pain

Generex signs oral insulin distribution deal with Dong-Sung for Korea

Invitrogen plans meeting for proposed merger with Applied Biosystems

Oxygen Biotherapeutics to meet with FDA for proposed phase IIb Oxycyte trial

QLT enters into exclusive license agreement with Reckitt for Atrigel technology

NeuroDiscovery reports results from phase IIa clinical trials of NSL-101 in dental surgery

Resverlogix initiates phase Ib/IIa program for RVX-208

Recent Janssen patent imparts new therapeutic agents for gastrointestinal disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.